[Differences in hemodynamic effects of the cardioselective beta-adrenoblocker acebutolol and non-selective beta-adrenoblocker propranolol in long-term antihypertensive therapy]. / Osnovnye razlichiia gemodinamicheskikh éffectov kardioselektivnogo beta-adrenoblokatora atsebutolola i neselektivnogo beta-adrenoblokatora propranolola pri dlitelnoi antigipertenzivnoi terapii.

The cardioselective beta-adrenoblocker acebutolol used as a course therapy for 12 weeks was found to be a highly beneficial antihypertensive agent. The antihypertensive effect of the agent given in doses of 400-800 mg/day was as pronounced and prolonged as that of propranolol, 80-160 mg/day, though there is a tendency for acebutolol to show its complete or partial antihypertensive effect rather at the end of monotherapy than propranolol. At the same time the bradycardiac effect was more pronounced in propranolol therapy. The antihypertensive effect of acebutolol, 400-800 mg/day, was revealed after 2 weeks of its use and persisted within the entire 12 weeks of therapy. The drug was well tolerated. In contrast to propranolol, a non-selective beta-adrenoblocker having no intrinsic sympathomimetic activity, acebutolol failed to produce adverse effects, such as by decreasing cardiac output and increasing total peripheral vascular resistance. The agent had a less negative chronotropic effect.

[The efficacy of proxodolol in patients with stable arterial hypertension]. / Effektivnost' proksodolola u bol'nykh stabil'noi arterial'noi gipertenziei.

The new original Russian drug proxodolol having alpha- and beta-adrenoblocking activities in a ratio of 1:100 was examined at Stages I and II of clinical trials. The drug was given to 29 male patients aged 30-63 years who suffered from Stages I and II persistent hypertensive disease with a baseline diastolic blood pressure of >95 mm Hg. Proxodolol as 10- and 40-mg tablets was demonstrated to be an effective antihypertensive agent, its antihypertensive effects being revealed in acute and chronic uses. The drug was well tolerated by the patients, causing no significant adverse reactions. Further comprehensive comparative controlled studies of proxodolol including larger patient groups will define the contribution of the drug in long-term antihypertensive prophylaxis.

[The antihypertensive effect of the new cardioselective prolonged-action beta-adrenoblocker bisoprolol compared with propranolol, metoprolol and placebo]. / Antigipertenzivnyi éffekt novogo kardioselektivnogo beta-adrenoblokatora prolongirovannogo deistviia bisoprolola v sravnenii s propranololom, metoprololom i platsebo.

The antihypertensive effect of daily doses of three beta-adrenoblockers (Bisoprolol, 10 mg once a day, propranolol, 80 mg twice a day, and methoprolol, 100 mg twice a day), and placebo was examined in 14 patients with persistent mild and moderate hypertension during a double blind cross-over study by using 24-hour monitoring of blood pressure and its routine measurements. The latter made by a mercury sphygmomanometer indicated that the antihypertensive and negative chronotropic effect of Bisoprolol in a dose of 10 mg remained 24 hours after its administration and it did not significantly differ from that of the two other agents given in the above doses. The application of 24-hour blood pressure monitoring allows a more pronounced antihypertensive effect of bisoprolol to be revealed during 24 hours than that displayed by the two agents. Bisoprolol is an effective and safe antihypertensive agent.